Management to Present Lead drug candidate to Industry and Venture Finance Executives
NEW YORK, April 12, 2016 /PRNewswire/ --
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to announce that its license technology partner, Mannin Research, will present at MATTER Midwest University HealthTech Showcase on April 12-13th, 2016. Mannin Research will present and discuss its glaucoma treatment technology at the forum to an audience of sophisticated healthcare investors.
The showcase is part of the opening reception for the MedCity INVEST conference. MedCity INVEST (formerly the MidAmerica Healthcare Venture Forum) is a national healthcare investing conference based in Chicago. MedCity INVEST is the premier national healthcare investing conference based in the Midwest, uniting active investors with corporate business development executives to facilitate investment opportunities with promising startups. For more than a decade, biotech, medical device, digital health, diagnostics, pharma and beyond have presented there to investors like AbbVie, Qualcomm Ventures, Mayo Clinic Ventures, Baxter, Baird, Venture Investors and beyond.
More than 300 industry leaders, venture capitalists and angel investors will be in attendance April 11-13 to discuss investment trends and interact with a number of promising early-stage start-up companies.
As part of their involvement with the Chicago-Canada Mentorship Program (C2MP), Mannin Research will be attending the MedCity INVEST conference. Mannin Research Inc. has also been selected to participate in the MATTER Midwest University HealthTech Showcase as part of the CIM@MATTER group of companies attending. MATTER is showcasing their top healthcare technologies at the official opening reception for the MedCity INVEST Conference. For more inforamtion on the event please visit their website http://events.medcitynews.com/invest/
Mannin’s CEO, Dr. George N. Nikopoulos stated, “We are looking forward to discussing Mannin’s innovative solution for the treatment of glaucoma with industry leaders and investors at the Showcase on Monday and throughout the MedCity invest conference this week. This opportunity would not be possible without the C2MP and the CIM@MATTER program teams, and we thank them for their support.”
Denis Corin, CEO of Q BioMed Inc. said, “This is a unique opportunity to present our innovative glaucoma therapeutic platform to pharma industry executives, venture capital funds and angel investors.”
In October 2015 Q BioMed Inc entered into an agreement with Mannin Research to exclusively license, with an option to acquire, the platform technology assets of Mannin Research, the developer of a new class of vascular therapeutics. Mannin’s primary focus is developing a first-in-class therapeutic eye-drop for glaucoma in adults and children, using a research platform designed to help develop new drugs for that indication and cystic kidney disease, among other diseases. Lead drug candidate MAN-01 is designed to treat abnormal vessels within the eye - thus treating glaucoma at its root causes.
We invite our shareholders and interested parties to subscribe to our email list and stay informed on our website at http://www.qbiomed.com and follow us on the social media feeds we use.
About Q BioMed Inc.
Q BioMed Inc. “Q” is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.
Forward-Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435
